Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30013736HIVENSG00000198785.7protein_codingGRIN3ANoNo116443Q8TCU5
TVIS30084755HIVENSG00000198785.7protein_codingGRIN3ANoNo116443Q8TCU5
TVIS30085254HIVENSG00000198785.7protein_codingGRIN3ANoNo116443Q8TCU5
TVIS30071468HIVENSG00000198785.7protein_codingGRIN3ANoNo116443Q8TCU5
TVIS20063716HPVENSG00000198785.7protein_codingGRIN3ANoNo116443Q8TCU5
TVIS20041159HPVENSG00000198785.7protein_codingGRIN3ANoNo116443Q8TCU5
TVIS20038820HPVENSG00000198785.7protein_codingGRIN3ANoNo116443Q8TCU5
TVIS20041908HPVENSG00000198785.7protein_codingGRIN3ANoNo116443Q8TCU5
TVIS44022934HTLV-1ENSG00000198785.7protein_codingGRIN3ANoNo116443Q8TCU5
TCGA Plot Options
Drug Information
GeneGRIN3A
DrugBank IDDB00915
Drug NameAmantadine
Target IDBE0000641
UniProt IDQ8TCU5
Regulation Typeantagonist
PubMed IDs15800186; 10443547
CitationsBlanpied TA, Clarke RJ, Johnson JW: Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci. 2005 Mar 30;25(13):3312-22.@@Hesselink MB, De Boer AG, Breimer DD, Danysz W: Adaptations of NMDA and dopamine D2, but not of muscarinic receptors following 14 days administration of uncompetitive NMDA receptor antagonists. J Neural Transm (Vienna). 1999;106(5-6):409-21.
GroupsApproved
Direct ClassificationMonoalkylamines
SMILESNC12CC3CC(CC(C3)C1)C2
Pathways
PharmGKBPA448360
ChEMBLCHEMBL660